Advertisement
Screener

MADRIGAL PHARMACEUTICALS, INC. (MDGL) ROA

MADRIGAL PHARMACEUTICALS, INC. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • MADRIGAL PHARMACEUTICALS, INC. roa for the quarter ending 2026-06-30 was -26.12%, a change of 1.64% year-over-year.
  • MADRIGAL PHARMACEUTICALS, INC. roa for the quarter ending 2026-03-31 was -25.21%, a change of 14.08% year-over-year.
  • MADRIGAL PHARMACEUTICALS, INC. roa for the quarter ending 2025-12-31 was -22.89%, a change of 21.81% year-over-year.
  • MADRIGAL PHARMACEUTICALS, INC. roa for the quarter ending 2025-09-30 was -21.22%, a change of 27.11% year-over-year.
  • MADRIGAL PHARMACEUTICALS, INC. roa for fiscal 2025 was -22.89%, a change of 21.81% from fiscal 2024.
  • MADRIGAL PHARMACEUTICALS, INC. roa for fiscal 2024 was -44.70%, a change of 13.63% from fiscal 2023.
  • MADRIGAL PHARMACEUTICALS, INC. roa for fiscal 2023 was -58.33%, a change of 23.13% from fiscal 2022.
  • MADRIGAL PHARMACEUTICALS, INC. roa for fiscal 2022 was -81.46%, a change of 7.02% from fiscal 2021.
Available history
2016-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-26.12%-$325.1M-$57.94M$1.24B
2026-03-31-25.21%-$309.44M-$94.39M$1.23B
2025-12-31-22.89%-$288.28M-$58.58M$1.26B
2025-09-30-21.22%-$289.13M-$114.19M$1.36B
2025-06-30-27.76%-$281.9M-$42.28M$1.02B
2025-03-31-39.29%-$391.59M-$73.24M$996.63M
2024-12-31-44.70%-$465.89M-$59.42M$1.04B
2024-09-30-48.33%-$518.67M-$106.96M$1.07B
2024-06-30-46.41%-$510.45M-$151.97M$1.1B
2024-03-31-41.05%-$444.28M-$147.54M$1.08B
2023-12-31-58.33%-$373.63M-$112.19M$640.55M
2023-09-30-145.96%-$347.34M-$98.74M$237.96M
2023-06-30-109.04%-$329.8M-$85.80M$302.46M
2023-03-31-94.67%-$314.73M-$76.90M$332.45M
2022-12-31-81.46%-$295.35M-$85.91M$362.57M
2022-09-30-172.71%-$273.99M-$81.20M$158.64M
2022-06-30-118.26%-$255.9M-$70.73M$216.39M
2022-03-31-110.85%-$246.82M-$57.52M$222.66M
2021-12-31-88.48%-$241.85M-$64.55M$273.33M
2021-09-30-77.59%-$236.42M-$63.10M$304.7M
2021-06-30-70.52%-$231.28M-$61.65M$327.96M
2021-03-31-70.60%-$218.66M-$52.55M$309.73M
2020-12-31-70.47%-$202.24M-$59.12M$287M
2020-09-30-50.31%-$170.86M-$57.96M$339.62M
2020-06-30-34.59%-$134.33M-$49.02M$388.39M
2020-03-31-25.52%-$105M-$36.13M$411.46M
2019-12-31-18.99%-$83.95M-$27.74M$442.06M
2019-09-30-14.83%-$67.68M-$21.43M$456.25M
2019-06-30-11.66%-$54.77M-$19.70M$469.82M
2019-03-31-8.66%-$41.53M-$15.08M$479.56M
2018-12-31-6.76%-$32.81M-$11.47M$485.43M
2018-09-30-6.08%-$29.78M-$8.51M$489.55M
2018-06-30-6.03%-$29.63M-$6.46M$491.53M
2018-03-31-17.18%-$31.52M-$6.36M$183.48M
2017-12-31-16.20%-$31.15M-$8.45M$192.31M
2017-09-30-48.48%-$30.46M-$8.36M$62.83M
2017-06-30-53.10%-$36.14M-$8.35M$68.07M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-22.89%-$288.28M$1.26B
2024-12-31-44.70%-$465.89M$1.04B
2023-12-31-58.33%-$373.63M$640.55M
2022-12-31-81.46%-$295.35M$362.57M
2021-12-31-88.48%-$241.85M$273.33M
2020-12-31-70.47%-$202.24M$287M
2019-12-31-18.99%-$83.95M$442.06M
2018-12-31-6.76%-$32.81M$485.43M
2017-12-31-16.20%-$31.15M$192.31M
2016-12-31-64.03%-$26.39M$41.21M

Similar stocks

Stock NameCountryMarket CapPE Ratio
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05